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Abstract
Background: Nausea and vomiting are frequently seen in patients undergoing cesarean section (CS) under regional anesthesia.
We aimed to compare the antiemetic efficacy of  ondansetron and dexamethasone combination with that of  the use of  each
agent alone to decrease the incidence of post-delivery intraoperative nausea and vomiting (IONV) during CS under spinal
anesthesia.
Objective: To compare the antiemetic efficacy of  ondansetron and dexamethasone combination with that of  the single use
of each agent to decrease the incidence of postdelivery IONV during CS under spinal anesthesia.
Methods: A randomized, prospective, double blind study was performed on 90 patients undergoing planned CS under
spinal anesthesia. Patients received 4mg ondansetron in Group O, 8mg dexamethasone in GroupD, 4mg ondansetron+8mg
dexamethasone in Group OD intravenously within 1-2 minutes after the umbilical cord was clamped. Frequency of post-
delivery IONV episodes was recorded.
Results: A total of  86 eligible patients were included in the study. There were 29 patients in Group O, 29 patients in Group
D and 28 patients in Group OD. There were no statistically significant difference between the groups in terms of  baseline
characteristics and intraoperative managements. Frequency of intraoperative nausea, retching and vomiting experiences were
similar between the groups(p>0.05).
Conclusion: Single dose 4mg ondansetron, 8mg dexamethasone, or combined use of 8mg dexamethasone+4mg
ondansetron, given intravenously is all effective agents for the control of  postdelivery IONV. Combined use of  dexamethasone
and ondansetron for the same indication does not seem to increase the antiemetic efficacy.
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Introduction
Nausea and vomiting is seen in almost 80% of the
patients undergoing cesarean section (CS) under
regional anesthesia1-3. Many different factors like
psychogenic factors, surgical procedure itself, traction
of the visceral peritoneum, uncorrected hypotension,
administration of opioid drugs and uterotonic agents
can lead to nausea and vomiting4-6. Antiemetic drugs
can be used in the management of intraoperative
nausea and vomiting (IONV) and they are generally
administered after the umbilical cord is clamped2,7-9.
Ondansetron is a selective antagonist of the 5-
hydroxytryptamine3 (5-HT
3
) receptors and is a very
effective agent in the prevention and treatment of
nausea and vomiting. It is effective in the prevention
and treatment of chemotherapy induced10,
intraoperative7  and postoperative nausea and
vomiting11,12 . It decreases the nausea and vomiting
that occurs during CS but it cannot completely control
the symptoms.
Dexamethasone is a corticosteroid with
antiemetic and high anti-inflammatory effects. Use
of dexamethasone in combination with the other
drugs has been reported to increase the antiemetic
or analgesic efficacy, and minimal side effects have
been reported when it is used as a single agent 13-16.
The mechanism for the antiemetic effect of
dexamethasone has been incompletely understood
but it is thought to be caused by the inhibition of
prostaglandin synthesis, by showing anti-
inflammatory efficacy and by causing a decrease in
the release of endogenous opiates17,18. As an
antiemetic agent, it has been used at a dose ranging
between 2.5-10 mg/day19,20.
Since nausea and vomiting can occur by a variety of
different mechanisms, combinations of different
antiemetics are used to prevent or treat these
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symptoms 6,21. By the help of these combinations,
multiple routes that can lead to nausea and vomiting
can be blocked22. Effect of addition of
dexamethasone to ondansetron in the control of
postoperative nausea and vomiting (PONV) has been
studied before , but we could not find any study in
the literature that investigated the efficacy of this
combination for the control of  postdelivery IONV.
In this study, we aimed to compare the antiemetic
efficacy of ondansetron and dexamethasone
combination with that of the single use of each agent
to decrease the incidence of postdelivery IONV
during CS under spinal anesthesia.
Methods
Approval from the clinical research ethics committee
of Abant Izzet Baysal University was obtained
before the initiation of  the study. All participants
provided a written informed consent. This
randomized, prospective, double blind, study was
performed on 90 ASA physical status I-II female
patients, between 20-40 years of age undergoing a
planned CS under spinal anesthesia. Patients with a
gastrointestinal disease, drug allergies, infection,
diabetes, glaucoma, preeclampsia, eclampsia, a
psychiatric disorder and those patients who took an
antiemetic agent in the last 24 hours were excluded
from the study.
Antiemetic drugs were prepared as a 5mL
solution diluted with normal saline in similar syringes,
by a second anesthetist at the initiation of surgery at
a separate room and there were also syringes which
included only 5mL of  normal saline. Two syringes
were given by the second anesthetist to the anesthetist
who was unaware of the content of the syringe and
would administer it in a double-blind fashion. A total
of 30 patients were randomly allocated to each of
the 3 groups. The randomization was performed
by the use of sequentially numbered, opaque, sealed
envelopes. Patients received either 4 mg ondansetron
(Zofer 2ml/4mg, Adeka) diluted to 5mL by normal
saline + 5mL normal saline (Group O), 8 mg
dexamethasone (Deksamet 2ml/8mg, Osel) diluted
to 5mL by normal saline + 5mL normal saline
(group D) or 4 mg ondansetron diluted to 5mL by
normal saline + 8 mg dexamethasone diluted to 5mL
by normal saline (Group OD)  intravenously, within
1-2 minutes after the umbilical cord was clamped.
At the operating room, initially, standard
monitorization that included electrocardiogram, non-
invasive arterial blood pressure measurement and
pulse oximetry was applied to all patients. All patients
received 15-20 mL/kg (1500 ml maximum) normal
saline before the intervention. Spinal anesthesia was
performed using a 25-gauge spinal needle (Braun
Melsungen, Germany), while the patient is in the sitting
position, through the L3-4 interspace (or alternatively
through the L2-3 or L4-5 interspaces).  2.4-2.8 mL
(depending on patients height) of 0.5% heavy
marcaine (Marcaine Spinal Heavy Ampul %0.5,
Astrazenaca) was administered to the subarachnoid
space. Patients were than moved to supine position,
and to prevent spinal anesthesia induced hypotension,
patients were infused normal saline at a rate of  125
ml/hr, operation table was given a 15-20 degrees
left lateral tilt to decrease the aortocaval compression
caused by the uterus. Oxygen was delivered to all
patients at a rate of 2-3 L/ min via a face mask.
Before the surgical incision, the level of sensorial
blockage was evaluated by pinprick test, and the
highest level of  blockade was determined. Patients
in whom the level of analgesia was insufficient were
excluded from the study, and were given general
anesthesia.   Non-invasive blood pressure
measurements were obtained from each patient at
1-3 min intervals, and in case of  hypotension blood
pressure measurement intervals were shortened to
1 min. We have assumed that systolic blood pressure
<100 mmHg or >20% decrease in systolic blood
pressure as hypotension. We treated hypotension with
increasing the infusion rate of  normal saline, and
administering 5-10 mg of intravenous ephedrine
(Efedrin Ampul 1 ml/50 mg, Osel) in necessary cases
was planned. After delivery of the fetus, 10 units of
oxytocin/500 mL 0.9% normal saline administered
at a rate of 125mL/hour to increase the uterine
contractility.
During the intraoperative post-delivery
period, nausea, retching and vomiting episodes were
recorded by an anesthetist who was blinded to the
drug administered to the patient. Besides questioning
the patient in every 3 minutes about these emetic
symptoms, the patient was also requested to report
the symptoms that occur at the intervals. Drug related
complications were recorded during the study period.
A standardized surgical technique was used in all
cesarean section’s except for the tubal ligation
procedure performed in some but not all of  the
cases.
For the statistical analysis, SPSS software for
Windows version 15.0 (SPSS Inc., Chicago, IL, USA)
was used. All sample sizes and power calculations
were 2-tailed with an á level of .05. The original
sample size of  75 individuals permitted 91% and
89% power for detecting effect sizes of 0.2 and 0.3,
respectively. The target sample size of  90 individuals
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included an anticipated 10% dropout in the best
medical therapy group. Continuous data are
presented as mean ± standard deviation. One-way
ANOVA test and t test were used for parametric
data analysis, and Kruskal-Wallis test, Mann Whitney
U test, Chi-square and Fisher’s exact tests were used
to analyze non-parametric data. P <0.05 was
considered statistically significant.
Results
A total of 90 patients were initially included in the
study. Two patients were excluded from the study
because of a low level of sensorial blockade as
detected by the pinprick test. In spite of a sufficient
level of sensorial blockade, two patients were also
excluded from the study since they required sedation
with propofol. The remaining 86 eligible patients,
29 were in Group O, 29 were in Group D and 28
were in Group OD (figure 1).
Levels of the sensorial blockade of the 86
patients were sufficient for the surgical procedure
and were between T2 and T6 with no significant
difference between the groups (p>0.05) (table 2).
All patients included in the study had an
uncomplicated CS. There were no significant
differences between the groups in terms of  baseline
patient characteristics (p>0.05) (table 1), and
intraoperative managements (p>0.05) (table 2).
Figure 1: Study profile








Age, years 30±6 29±4 29±4
Weight, kg 74±12 73±11 79±14
Height, cm 161±4 162±6 162±5
Gestational age (weeks) 37±1 37±1 37±1
Multiparous (%) 17(58) 22(75) 18(64)
Smoking (%) 3(10) 3(10) 4(14)
History of motion sickness (%) 3(10) 9(31) 7(25)
History of previous postoperative 
emesis (%)
5(17) 2(7) 3(11)
Baseline blood pressure (mm Hg) 121±13 118±15 120±13
Values are expressed as means ±SD, numbers or numbers (%) of  patients.
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Table 2: Information about the intraoperative managements, ephedrine needs for the correction of










Uterus exteriorization, n 29 29 28
Operation time (min) 35±10 35±12 41±14
Uterus exteriorization time (min) 3.6±1.6 4.1±2.2 3.9±1.6
I-D Interval (min) 2.5±1.5 3±1.9 2.9±1.6
U-D Time (sec) 49±37 44±34 51±38
Tubal ligation during cesarean section 
(%)
7(24.1) 1(3.4) 5(17.9)
Number of patients  that had 






Values are expressed as means ±SD, numbers or numbers (%) of  patients.
I-D interval: interval from skin incision to delivery of  fetus, U-D interval: interval from uterine incision to
delivery of fetus
Of  the 86 patients, tubal ligation was performed in
13 of  the cases. The operation duration of  patients
that had undergone tubal ligation was significantly
longer than those who had not undergone this
procedure (p=0.01) (table 4). But, there was no
significant difference between the incidence of emetic
symptoms of the patients that had or had not
undergone tubal ligation in spite of different durations
of  surgery (p>0.05) (table 4). Four (14%) patients in
Group O, 2 (7%) patients in Group D and 7 (25%)
patients in Group OD had hypotension all of which
occurred after the delivery period. There was no
difference between the incidence of intraoperative
emetic symptoms of the patients between the
groups (p>0.05) (table 3).  86.2% of patients in
Group O, 72.4% of  patients in Group D and
64.3% of patients in Group OD were free of these
symptoms. One patient from Group D exhibited
vomiting and  none from the other groups.
Extrapyramidal side effects or cardiac arrhythmias
occurred in none of  the patients. Transient headache
lasting less than 10 minutes was the most common
side effect and was observed in 2 patients from
group O and 3 patients from Group OD.
Table 3: Comparison of  the duration of  surgery and the frequency of  emetic symptoms between
patients that had or had not undergone tubal ligation
With tubal 





Operation time (min) 36±12.5 44±11 0.01
Incidence of nausea 3(23) 19(26) 0.563
Incidence of retching 2(15.3) 5 (6.8) 0.285
Incidence of vomiting 0(0) 1 (1) 0.849
Values are expressed as means ±SD or numbers (%) of  patients.
African Health Sciences Vol 13  Issue 2 June  2013 479










Number of  patients 29 29 28
No symptoms (no nausea, 
retching, or vomiting) 
25(86.2) 21(72.4) 18(64.3) 0.158
Incidence of  Nausea 4(13.8) 8(27.6) 10(35.7) 0.694
Incidence of  Retching 3(10.3) 3(10.3) 1(3.6) 0.570
Incidence of  Vomiting 0(0) 1(3.4) 0(0) 0.366
Values are expressed as numbers or numbers (%) of  patients.
Discussion
This randomized, prospective, double blind study
demonstrated that CSs performed under spinal
anesthesia using 8 mg intravenous dexamethasone
as a single agent for the control of postdelivery
IONV is as effective as 4 mg ondansetron with no
increase in the side effect profile. Combined use of
these agents for the same indication does not seem
to increase the efficacy when compared with the
ondansetron or dexamethasone alone.
The precise etiology of  IONV remains
unknown and various factors have been implicated4-
6. Hypotension is probably the most important cause
of IONV that occurs during CS under spinal
anesthesia. Hypotension can induce the emetic
symptoms by leading to cerebral hypoperfusion6.
Prevention of hypotension is therefore important
for the prevention of  IONV.  We tried to take the
necessary measures to prevent hypotension in all of
our patients. Although recent studies favor the use
of phenylephrine over ephedrine for the control of
intraoperative hypotension23, we could not use this
drug since it is not commercially found in our country.
In our study we especially evaluated the incidence
of  post delivery IONV. Because the nausea and
vomiting before the delivery period is especially
related with spinal anesthesia induced hypotension
which can be prevented by performing the necessary
preventive measures. Besides, in our cases, in contrast
to those reported in the previous studies7,9  interval
from skin incision to delivery of  fetus and the interval
from uterine incision to delivery of fetus in all groups
were very short. So the predelivery period was very
short in the present study. Depending on our
previous observations, we thought that it would be
better to investigate the nausea and vomiting in the
postdelivery period which is more difficult to control.
Although majority of hypotension during spinal
anesthesia for CS occur before the delivery period,
none of our patients experienced hypotension during
this period as a result of adequate preventive
measures. All of  the hypotension cases in our study
occurred after the delivery period. All patients
developing hypotension also showed emetic
symptoms sequentially, which resolved
simultaneously within a short time with the correction
of hypotension.
The baseline characteristics and
intraoperative managements of all participants in the
groups were similar in our study. The surgical
procedure was standard in all of the cases except
performance of  tubal ligation in some of  the cases,
and this caused a prolongation in the duration of
surgery. But, we found that this prolongation had
no effect in the incidence of  post delivery IONV.
Ondansetron is a potent antiemetic agent which has
been effectively used for the control of IONV and
PONV. In clinical practice, it is commonly used at a
dose of 4 mg intravenously9,24-28. Dershwitz et al.
studied 6 different doses of ondansetron for the
prevention of PONV and they recommended the
4 mg dose as a result of their study 26.  Abouleish et
al. found that use of 4 mg ondansetron during CS
decreased the occurrence of the emetic symptoms
significantly when compared with the placebo (%36
vs. %58)24. In our study we also used ondansetron at
a dose of  4 mg and the emetic symptoms observed
in Group O was similar to the previous studies.
Combined use of antiemetics can act from several
different ways in controlling nausea and vomiting
symptoms, and therefore can be more effective than
using single agents 22. Some studies in the literature
African Health Sciences Vol 13  Issue 2 June  2013480
compared the antiemetic efficacy of dexamethasone
for the prevention of PONV with other agents, or
investigated the efficacy of combining
dexamethasone with other antiemetic agents for the
same purpose. D’Souza et al. compared
dexamethasone with ondansetron for the prevention
of  PONV after laparoscopic gynecologic surgery
and found that dexamethasone decreased the
incidence of PONV and use of single dose of
dexamethasone was safe, had a lesser cost and could
be alternative to single dose ondansetron in this
patient population19. Bhattarai et al. compared use
of ondansetron alone with combined use of 4 mg
ondansetron plus 8mg dexamethasone in the control
of PONV in patients undergoing laparoscopic
surgery and found that the combined use of two
agents was more effective25. The combination was
also safe and well tolerated by the patients. Several
other studies in the literature also demonstrated that
combined use of dexamethasone with other
antiemetics decreases the incidence of PONV14,15,29,30.
In our study we investigated the efficacy of 8 mg
dexamethasone alone or in combination with 4 mg
ondansetron for the control of  IONV. Since these 2
agents act by different antiemetic mechanisms, we
did not decrease the dosage of each agent during
combined therapy.  As emetic symptoms are
frequently observed in patients undergoing CS under
spinal anesthesia, we thought it would not be ethical
to form a placebo group for our study. Absence of
significant difference in the incidence of emetic
symptoms of patients in Group D from the other
groups shows, as in the previous studies19, that
dexamethasone is an effective antiemetic agent.
Incidence of emetic symptoms in Group OD was
slightly higher from the other groups although this
difference was not statistically significant. We thought
that this difference was due to a greater rate of
hypotension observed in this group which is
demonstrated in Table 2 by a higher need for
ephedrine use. Occurrence of transient headache in
2 patients from Group O and in 3 patients from
Group OD while it did not occur in any of the
patients in group D was an indicator that single dose
use of dexamethasone did not cause an increase in
the side effect profile and was well tolerated by the
patients.
The main limitation of the present study is
that we administered dexamethasone within 1-2
minutes after the umbilical cord was clamped. Wang
et al31 have shown that dexamethasone took long to
achieve its antiemetic effects.  This may explain why
there was lack of effect in the dexamethasone  and
ondansetron combined arm in our study.
Conclusion
Single dose 8mg dexamethasone or 4 mg ondansetron
given intravenously are both effective agents for the
control of  postdelivery IONV. However, combined
use of these agents does not seem to increase the
efficacy over that achieved by the single use of each
agent. Further randomized, controlled trials with a
larger sample size are needed to clarify the efficacy of
these agents in the control of  postdelivery IONV.
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